Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:MNKD NASDAQ:MRUS NASDAQ:PRVB NASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.54+6.2%$1.40$1.05▼$5.17$166.75M0.381.20 million shs622,965 shsMNKDMannKind$3.82+5.5%$4.17$3.51▼$7.63$1.16B0.962.44 million shs3.52 million shsMRUSMerus$54.51+4.2%$50.18$33.19▼$62.98$3.77B1739,442 shs1.30 million shsPRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shsVNDAVanda Pharmaceuticals$5.02+3.3%$4.47$3.81▼$6.37$295.83M0.68603,524 shs703,151 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-0.68%+2.84%-5.23%+19.83%+14.17%MNKDMannKind+2.26%+1.12%-17.35%-22.81%-32.84%MRUSMerus-0.48%-0.63%-6.90%+32.28%-6.07%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%VNDAVanda Pharmaceuticals-0.61%+3.85%+5.42%+17.68%-7.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.6211 of 5 stars3.62.00.00.02.61.70.6MNKDMannKind2.5268 of 5 stars3.61.00.00.00.51.71.9MRUSMerus2.0872 of 5 stars3.61.00.00.02.32.50.0PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/AVNDAVanda Pharmaceuticals4.3803 of 5 stars3.82.00.04.20.63.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$9.71530.80% UpsideMNKDMannKind 3.29Buy$10.33170.51% UpsideMRUSMerus 3.14Buy$84.6455.27% UpsidePRVBProvention Bio 0.00N/AN/AN/AVNDAVanda Pharmaceuticals 3.50Strong Buy$16.50228.69% UpsideCurrent Analyst Ratings BreakdownLatest MRUS, MNKD, VNDA, PRVB, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/23/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.005/28/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.005/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/14/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.005/14/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$13.005/13/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.005/7/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$17.78M9.38N/AN/A$1.44 per share1.07MNKDMannKind$297.60M3.90$0.15 per share25.51($0.29) per share-13.17MRUSMerus$54.73M68.93N/AN/A$9.46 per share5.76PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84VNDAVanda Pharmaceuticals$198.77M1.49N/AN/A$9.24 per share0.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)MNKDMannKind$27.59M$0.1038.2016.61N/A10.12%-32.41%10.85%8/6/2025 (Estimated)MRUSMerus-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/AVNDAVanda Pharmaceuticals-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)Latest MRUS, MNKD, VNDA, PRVB, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ACRSAclaris Therapeutics-$0.14N/AN/AN/A$1.34 millionN/A8/6/2025Q2 2025MNKDMannKind$0.04N/AN/AN/A$77.82 millionN/A7/30/2025Q2 2025VNDAVanda Pharmaceuticals-$0.34N/AN/AN/A$54.77 millionN/A5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/7/2025Q1 2025VNDAVanda Pharmaceuticals-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19-$0.12+$0.07-$0.12$3.55 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A5.065.06MNKDMannKindN/A2.362.11MRUSMerusN/A5.865.86PRVBProvention Bio0.191.931.92VNDAVanda PharmaceuticalsN/A3.933.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%MNKDMannKind49.55%MRUSMerus96.14%PRVBProvention Bio37.39%VNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%MNKDMannKind2.70%MRUSMerus4.57%PRVBProvention Bio13.10%VNDAVanda Pharmaceuticals8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million101.35 millionOptionableMNKDMannKind400303.93 million294.82 millionOptionableMRUSMerus3769.21 million66.05 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableVNDAVanda Pharmaceuticals29058.93 million53.69 millionOptionableMRUS, MNKD, VNDA, PRVB, and ACRS HeadlinesRecent News About These CompaniesVanda Pharmaceuticals (NASDAQ:VNDA) Stock Crosses Above 200-Day Moving Average - Should You Sell?July 2, 2025 | marketbeat.comVNDA - Vanda Pharmaceuticals Inc Chart - MorningstarJune 24, 2025 | morningstar.comMRisks of a blockade in the Strait of Hormuz 'remain absolutely minimalistic': Vanda InsightsJune 23, 2025 | youtube.comYInsider Selling: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells 7,000 Shares of StockJune 18, 2025 | insidertrades.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells $32,130.00 in StockJune 17, 2025 | marketbeat.comInsider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharmaceuticals Inc (VNDA)June 16, 2025 | gurufocus.comVanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to Hold at Wall Street ZenJune 14, 2025 | marketbeat.comBrokers Issue Forecasts for VNDA FY2026 EarningsJune 11, 2025 | marketbeat.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 10, 2025 | finanznachrichten.deVanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 10, 2025 | prnewswire.comVanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual MeetingMay 27, 2025 | prnewswire.comInsider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires 10,000 Shares of StockMay 22, 2025 | insidertrades.comInsider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Purchases 20,000 Shares of StockMay 20, 2025 | insidertrades.comInsider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA)May 20, 2025 | gurufocus.comVanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit ...May 16, 2025 | gurufocus.comVanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025May 16, 2025 | prnewswire.comVanda Pharmaceuticals (VNDA) Receives Overweight Rating from Cantor Fitzgerald | VNDA Stock NewsMay 14, 2025 | gurufocus.comVanda Pharmaceuticals (VNDA) Projected to Transform with Overweight Rating | VNDA Stock NewsMay 14, 2025 | gurufocus.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deVanda Pharmaceuticals’ Earnings Call: Growth Amid ChallengesMay 8, 2025 | tipranks.comVanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ...May 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRUS, MNKD, VNDA, PRVB, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.54 +0.09 (+6.21%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.03 (+2.27%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.MannKind NASDAQ:MNKD$3.82 +0.20 (+5.52%) Closing price 04:00 PM EasternExtended Trading$3.77 -0.05 (-1.28%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Merus NASDAQ:MRUS$54.51 +2.18 (+4.17%) Closing price 04:00 PM EasternExtended Trading$54.50 0.00 (-0.01%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Provention Bio NASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Vanda Pharmaceuticals NASDAQ:VNDA$5.02 +0.16 (+3.29%) Closing price 04:00 PM EasternExtended Trading$5.06 +0.04 (+0.80%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
